CAL
VERV

Capital Advisors Ltd’s Verve Therapeutics VERV Stock Holding History

Capital Advisors Ltd’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31
Closed – – 1503
2023
Q3 		$0 Buy
+31
New +$499 ﹤0.01% 1494
2022
Q4 		– Sell
-2
Closed – – 1666
2022
Q3 		$0 Buy
+2
New +$64 ﹤0.01% 1546

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital Advisors Ltd's VERV Position: Q4 2023 in Review

Capital Advisors Ltd sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 31 shares.

Capital Advisors Ltd first reported a position in VERV in Q3 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2023. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • Capital Advisors Ltd reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 31 Verve Therapeutics shares in Q4 2023.
  • Capital Advisors Ltd first reported a position in Verve Therapeutics in Q3 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's Verve Therapeutics position peaked at $0 in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Capital Advisors Ltd's 13F filing for Q4 2023, filed 2 Feb 2024.